JP2012080900A5 - - Google Patents

Download PDF

Info

Publication number
JP2012080900A5
JP2012080900A5 JP2012000185A JP2012000185A JP2012080900A5 JP 2012080900 A5 JP2012080900 A5 JP 2012080900A5 JP 2012000185 A JP2012000185 A JP 2012000185A JP 2012000185 A JP2012000185 A JP 2012000185A JP 2012080900 A5 JP2012080900 A5 JP 2012080900A5
Authority
JP
Japan
Prior art keywords
age
macular degeneration
related macular
individual
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012000185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012080900A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012080900A publication Critical patent/JP2012080900A/ja
Publication of JP2012080900A5 publication Critical patent/JP2012080900A5/ja
Pending legal-status Critical Current

Links

JP2012000185A 2004-11-18 2012-01-04 視覚障害を処置するための方法および組成物 Pending JP2012080900A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62936304P 2004-11-18 2004-11-18
US60/629,363 2004-11-18
US64947905P 2005-02-02 2005-02-02
US60/649,479 2005-02-02
US67234605P 2005-04-18 2005-04-18
US60/672,346 2005-04-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007543226A Division JP2008520242A (ja) 2004-11-18 2005-11-18 視覚障害を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2012080900A JP2012080900A (ja) 2012-04-26
JP2012080900A5 true JP2012080900A5 (https=) 2012-11-08

Family

ID=36578383

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007543226A Withdrawn JP2008520242A (ja) 2004-11-18 2005-11-18 視覚障害を処置するための方法および組成物
JP2012000185A Pending JP2012080900A (ja) 2004-11-18 2012-01-04 視覚障害を処置するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007543226A Withdrawn JP2008520242A (ja) 2004-11-18 2005-11-18 視覚障害を処置するための方法および組成物

Country Status (14)

Country Link
US (3) US20090017029A1 (https=)
EP (1) EP1836312B1 (https=)
JP (2) JP2008520242A (https=)
KR (1) KR101290621B1 (https=)
CN (2) CN102618644A (https=)
AT (1) ATE528410T1 (https=)
AU (1) AU2005314461B2 (https=)
BR (1) BRPI0518289A2 (https=)
CA (1) CA2588270A1 (https=)
CY (1) CY1112579T1 (https=)
DK (1) DK1836312T3 (https=)
ES (1) ES2375490T3 (https=)
IL (1) IL183284A (https=)
WO (1) WO2006062716A2 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505784A1 (en) 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US8012683B2 (en) 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
CA2638916A1 (en) * 2006-02-13 2007-08-23 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
JP5431151B2 (ja) * 2006-07-13 2014-03-05 ユニバーシティー オブ アイオワ リサーチ ファンデーション 血管障害および加齢黄斑変性症の治療および診断のための方法および試薬
AU2016204271B2 (en) * 2006-07-13 2018-04-19 University Of Iowa Research Foundation Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration
AU2007277125B2 (en) * 2006-07-26 2013-08-01 Yale University Diagnosis and treatment of age related macular degeneration
CN101173314B (zh) * 2006-10-18 2010-12-01 四川省医学科学院(四川省人民医院) 检测老年黄斑变性疾病的试剂盒
CN106188303A (zh) 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
GB0701213D0 (en) * 2007-01-23 2007-02-28 Univ Cardiff Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration
US7972787B2 (en) * 2007-02-16 2011-07-05 Massachusetts Eye And Ear Infirmary Methods for detecting age-related macular degeneration
CA2680344A1 (en) 2007-03-14 2008-11-20 Woodruff Emlen Humaneered anti-factor b antibody
JP5226256B2 (ja) * 2007-07-26 2013-07-03 ニプロ株式会社 加齢黄斑変性症の発症リスクの予測方法
EP2217720A4 (en) * 2007-11-01 2010-12-08 Univ Iowa Res Found RNA LOCUS ANALYSIS TO ASSESS THE STUNNING FOR AMD AND MPGNII
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN103333952B (zh) * 2008-11-05 2015-07-29 健泰科生物技术公司 年龄相关的黄斑变性中的遗传多态性
US20120115925A1 (en) * 2008-12-23 2012-05-10 Massachusetts Eye And Ear Infirmary Allelic Variants Associated with Advanced Age-Related Macular Degeneration
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 CFH 또는 ApoH를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
MX2012005151A (es) 2009-11-05 2012-08-23 Federico Ii University Of Naples Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
WO2011143637A1 (en) 2010-05-14 2011-11-17 The Regents Of The University Of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
WO2011153234A2 (en) * 2010-06-01 2011-12-08 University Of Kentucky Research Foundation Methods of inhibiting alu rna and therapeutic uses thereof
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
JP2014502953A (ja) 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
FR2988298A1 (fr) * 2012-03-23 2013-09-27 Lfb Biotechnologies Facteur h pour son utilisation comme molecule antioxydante
EP2855529A4 (en) 2012-05-24 2015-12-09 Alexion Pharma Inc HUMANIZED ANTI-FACTOR B ANTIBODIES
CN102707068B (zh) * 2012-05-31 2015-03-18 北京大学 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
JP5721150B2 (ja) * 2013-03-14 2015-05-20 学校法人 埼玉医科大学 加齢黄斑変性症の発症リスクの予測方法
HRP20181451T1 (hr) 2013-03-14 2018-12-28 Baxalta Incorporated Čimbenik h, namijenjen presađivanju
JP6484215B2 (ja) 2013-03-14 2019-03-13 バクスアルタ インコーポレイテッド 関節リウマチの治療のためのh因子
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
US20150093331A1 (en) * 2013-10-01 2015-04-02 OncoLock Co., Ltd. Biomarkers for breast cancer
KR102131973B1 (ko) * 2013-12-30 2020-07-08 주식회사 케이티 개인 건강관리 방법 및 시스템
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
CN106248969A (zh) * 2015-11-01 2016-12-21 李倩 一种用于检测眼科疾病的试剂盒及其检测方法
PT3384049T (pt) * 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
KR102011182B1 (ko) * 2016-10-07 2019-08-16 단국대학교 천안캠퍼스 산학협력단 익상편 과발현 유전자 및 이의 용도
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals,Inc. 投与レジメンならびに関連組成物および方法
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
EP3824095A4 (en) * 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
WO2020180147A2 (ko) * 2019-03-07 2020-09-10 (주)레티마크 나이관련 황반변성 진단용 복합 마커 및 이의 용도
CA3167756A1 (en) * 2020-02-04 2021-08-12 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors
KR102333953B1 (ko) * 2020-07-10 2021-12-02 인제대학교 산학협력단 신규한 황반변성 진단용 유전자 마커
CN113293206A (zh) * 2021-07-23 2021-08-24 西安医臻生物医药科技有限公司 一种快速鉴别老年黄斑病变风险的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA2336703A1 (en) * 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
US20020032319A1 (en) * 2000-03-07 2002-03-14 Whitehead Institute For Biomedical Research Human single nucleotide polymorphisms
AU2001261103B2 (en) * 2000-04-29 2007-08-23 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CN1466953A (zh) * 2003-01-15 2004-01-14 哈佛东方生物医药(云南)有限公司 预防治疗老年黄斑变性的复合制剂
EP2357254A1 (en) * 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration

Similar Documents

Publication Publication Date Title
JP2012080900A5 (https=)
Calero et al. Apolipoprotein E genotyping method by Real Time PCR, a fast and cost-effective alternative to the TaqMan® and FRET assays
Awe et al. Evaluation of two MiniSTR loci mutation events in five Father-Mother-Child trios of Yoruba origin
WO2007130519A3 (en) Viral nucleic acid microarray and method of use
JP2012503985A5 (https=)
JP2017501685A5 (https=)
JP2014533949A5 (https=)
JP2019516375A5 (https=)
JP2010075182A5 (https=)
US10683548B2 (en) Single nucleotide polymorphism in HLA-B*15:02 and use thereof
JP2010528590A5 (https=)
RU2018122965A (ru) Улучшенный способ и набор для определения тяжести и прогрессирования периодонтального заболевания
JP2013544536A5 (https=)
RU2014126423A (ru) Высокопроизводительный анализ однонуклеотидных полиморфизмов
Schorderet et al. IROme, a New High‐Throughput Molecular Tool for the Diagnosis of Inherited Retinal Dystrophies
JP2016512041A5 (https=)
JP2010035532A (ja) アレル特異的pcr法
Ngoi et al. High Resolution Melting Analysis for Rapid Mutation Screening in Gyrase and Topoisomerase IV Genes in Quinolone‐Resistant Salmonella enterica
JP2013074888A (ja) IL28B(rs8099917)とITPA(rs1127354)の変異を検出する方法
Chan et al. Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting
Smelaya et al. Search for common molecular genetic markers of nosocomial pneumonia and acute respiratory distress syndrome
Mehta et al. High resolution melting (HRM) of forensically informative SNPs
Zhang et al. Analytical validation of a personalized medicine APOL1 genotyping assay for nondiabetic chronic kidney disease risk assessment
CN104293968A (zh) 一组用于检测非综合征性唇腭裂遗传易感性的多态性位点及检测试剂盒
Koehler et al. High‐throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real‐time PCR